PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo
Hiromasa Kuroda1, Seiji Mabuchi1, Katsumi Kozasa1
1Department of Obstetrics & Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Aim:
To evaluate the ability of PM01183 to eliminate myeloid-derived suppressor cells (MDSCs).
Materials & Methods:
The effect of PM01183 on MDSCs, NK cells and CD8+ T cells was examined in vitro and in vivo. The mechanism by which PM01183 depletes MDSCs was also investigated.
Results:
PM01183 reduced the number of MDSCs by inducing apoptosis and attenuated the MDSC-mediated suppression of CD8+ T cells by inhibiting arginase-1 production, whereas no significant effect on CD8+ T or NK cells was noted. The inhibitory effect of PM01183 on MDSC was mediated by the attenuation of STAT3 phosphorylation. The inhibitory effect of PM01183 on MDSCs was greater than those of existing anticancer agents.
Conclusion:
PM01183 exhibits strong inhibitory effects on MDSCs.
Insights
PM01183 effectively eliminates myeloid-derived suppressor cells (MDSCs) by inducing apoptosis and inhibiting their suppressive functions. This novel agent shows greater efficacy than existing treatments, offering a promising new avenue for cancer therapy.
Area of Science:
- Immunology
- Cancer Biology
- Pharmacology
Background:
- Myeloid-derived suppressor cells (MDSCs) are critical regulators of the tumor microenvironment, promoting immune evasion and cancer progression.
- Targeting MDSCs represents a promising strategy to enhance anti-tumor immunity and improve therapeutic outcomes in cancer patients.
Purpose of the Study:
- To evaluate the efficacy of PM01183 in eliminating MDSCs.
- To elucidate the underlying mechanisms of PM01183-mediated MDSC depletion.
- To compare the anti-MDSC activity of PM01183 with existing anticancer agents.
Main Methods:
- In vitro and in vivo studies were conducted to assess the effects of PM01183 on MDSCs, NK cells, and CD8+ T cells.
- Apoptosis induction, arginase-1 production, and STAT3 phosphorylation were analyzed to understand the mechanism of action.
- Comparative efficacy was determined against established anticancer drugs.
Main Results:
- PM01183 significantly reduced MDSC numbers through apoptosis induction.
- The drug attenuated MDSC-mediated suppression of CD8+ T cells by inhibiting arginase-1 production.
- PM01183's inhibitory effect on MDSCs was mediated by STAT3 phosphorylation inhibition and demonstrated superior efficacy compared to current anticancer agents.
- No significant impact on CD8+ T or NK cells was observed.
Conclusions:
- PM01183 exhibits potent inhibitory effects on MDSCs, highlighting its potential as an immunomodulatory agent in cancer therapy.
- The drug's ability to overcome MDSC-mediated immunosuppression offers a novel therapeutic approach for enhancing anti-tumor immune responses.
More Related Videos
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
08:00A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016